Want to see HK:1167 full AI Analyst Report?
Jacobio Pharmaceuticals Group Co., Ltd. (1167) Ratios
Jacobio Pharmaceuticals Group Co., Ltd. Ratios
HK:1167's free cash flow for Q2 2026 was $601.35M. For the 2026 fiscal year, HK:1167's free cash flow was decreased by $-112.12K and operating cash flow was $601.46M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.10 | 4.89 | 5.70 | 8.59 | 20.29 |
| Quick Ratio | 5.10 | 4.88 | 5.70 | 8.59 | 20.16 |
| Cash Ratio | 4.17 | 4.84 | 5.57 | 8.24 | 19.02 |
| Solvency Ratio | -0.22 | -0.33 | -0.86 | -1.23 | -3.43 |
| Operating Cash Flow Ratio | -0.82 | -0.31 | -1.78 | -1.88 | -1.82 |
| Short-Term Operating Cash Flow Coverage | -33.03 | -1.32 | -4.95 | 0.00 | 0.00 |
| Net Current Asset Value | $ 620.35M | $ 752.63M | $ 781.30M | $ 1.05B | $ 1.55B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.13 | 0.11 | 0.14 | 0.09 | 0.00 |
| Debt-to-Equity Ratio | 0.21 | 0.16 | 0.20 | 0.12 | 0.00 |
| Debt-to-Capital Ratio | 0.18 | 0.14 | 0.16 | 0.10 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.10 | 0.02 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.69 | 1.47 | 1.36 | 1.23 | 1.05 |
| Debt Service Coverage Ratio | -7.83 | -2.98 | -3.98 | -156.74 | -510.26 |
| Interest Coverage Ratio | -13.15 | -22.40 | -47.87 | -173.66 | -562.30 |
| Debt to Market Cap | 0.02 | 0.08 | 0.03 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.23 | 0.21 | 0.28 | 0.20 | 0.01 |
| Net Debt to EBITDA | 5.45 | 5.32 | 2.87 | 3.19 | 5.28 |
| Profitability Margins | |||||
| Gross Profit Margin | 56.28% | 100.00% | 5.04% | 13.20% | 8.40% |
| EBIT Margin | -317.76% | -130.49% | -552.28% | -386.01% | -196.73% |
| EBITDA Margin | -274.02% | -123.54% | -512.79% | -371.60% | -189.67% |
| Operating Profit Margin | -317.76% | -120.85% | -626.38% | -411.72% | -209.01% |
| Pretax Profit Margin | -272.73% | -100.00% | -565.36% | -388.38% | -197.10% |
| Net Profit Margin | -272.73% | -100.00% | -565.36% | -388.38% | -197.10% |
| Continuous Operations Profit Margin | -272.73% | -100.00% | -565.36% | -388.38% | -197.10% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 85.83% | 82.75% | 90.26% | 94.33% | 94.30% |
| Return on Assets (ROA) | -10.90% | -11.46% | -24.59% | -23.62% | -17.49% |
| Return on Equity (ROE) | -18.44% | -16.87% | -33.46% | -28.99% | -18.40% |
| Return on Capital Employed (ROCE) | -15.36% | -16.86% | -31.69% | -27.78% | -19.46% |
| Return on Invested Capital (ROIC) | -15.15% | -15.92% | -29.62% | -27.53% | -19.40% |
| Return on Tangible Assets | -10.90% | -11.46% | -24.61% | -23.63% | -17.51% |
| Earnings Yield | -3.21% | -16.85% | -14.17% | -10.71% | -3.41% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.90 | 16.68 | 6.80 | 6.37 | 2.35 |
| Payables Turnover | 0.52 | 0.24 | 0.74 | 0.86 | 2.74 |
| Inventory Turnover | 0.00 | 7.37 | 0.00 | 0.00 | 13.49 |
| Fixed Asset Turnover | 0.40 | 1.03 | 0.29 | 0.47 | 3.66 |
| Asset Turnover | 0.04 | 0.11 | 0.04 | 0.06 | 0.09 |
| Working Capital Turnover Ratio | 0.06 | 0.16 | 0.06 | 0.07 | 0.09 |
| Cash Conversion Cycle | -635.32 | -1429.51 | -437.65 | -366.71 | 49.02 |
| Days of Sales Outstanding | 61.87 | 21.88 | 53.66 | 57.31 | 155.07 |
| Days of Inventory Outstanding | 0.00 | 49.51 | 0.00 | 0.00 | 27.06 |
| Days of Payables Outstanding | 697.19 | 1500.90 | 491.32 | 424.02 | 133.11 |
| Operating Cycle | 61.87 | 71.39 | 53.66 | 57.31 | 182.13 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.24 | -0.10 | -0.47 | -0.39 | -0.20 |
| Free Cash Flow Per Share | -0.24 | -0.11 | -0.52 | -0.41 | -0.21 |
| Dividend Paid and CapEx Coverage Ratio | -173.77 | -6.13 | -9.42 | -17.72 | -13.25 |
| Capital Expenditure Coverage Ratio | -173.77 | -6.13 | -9.42 | -17.72 | -13.25 |
| Operating Cash Flow Coverage Ratio | -1.13 | -0.49 | -1.73 | -1.98 | -21.67 |
| Operating Cash Flow to Sales Ratio | -3.57 | -0.48 | -5.73 | -3.05 | -0.97 |
| Free Cash Flow Yield | -4.23% | -9.33% | -15.89% | -8.90% | -1.80% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -31.79 | -5.94 | -7.06 | -9.34 | -29.30 |
| Price-to-Sales (P/S) Ratio | 84.99 | 5.94 | 39.91 | 36.27 | 57.75 |
| Price-to-Book (P/B) Ratio | 5.75 | 1.00 | 2.36 | 2.71 | 5.39 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -23.66 | -10.72 | -6.29 | -11.24 | -55.63 |
| Price-to-Operating Cash Flow Ratio | -23.80 | -12.47 | -6.96 | -11.87 | -59.83 |
| Price-to-Earnings Growth (PEG) Ratio | 3.18 | 0.11 | 1.15 | -0.41 | 0.33 |
| Enterprise Value Multiple | -25.57 | 0.51 | -4.92 | -6.57 | -25.17 |
| Enterprise Value | 3.65B | -98.28M | 1.60B | 2.34B | 7.29B |
| EV to EBITDA | -25.57 | 0.51 | -4.92 | -6.57 | -25.17 |
| EV to Sales | 70.06 | -0.63 | 25.22 | 24.40 | 47.73 |
| EV to Free Cash Flow | -19.51 | 1.14 | -3.98 | -7.56 | -45.98 |
| EV to Operating Cash Flow | -19.62 | 1.33 | -4.40 | -7.99 | -49.45 |
| Tangible Book Value Per Share | 0.99 | 1.19 | 1.39 | 1.70 | 2.19 |
| Shareholders’ Equity Per Share | 1.00 | 1.19 | 1.39 | 1.71 | 2.19 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.07 | 0.20 | 0.08 | 0.13 | 0.20 |
| Net Income Per Share | -0.18 | -0.20 | -0.46 | -0.49 | -0.40 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.86 | 0.77 | 1.02 | 1.01 | 1.00 |
| Research & Development to Revenue | 3.17 | 2.12 | 5.86 | 4.65 | 1.84 |
| SG&A to Revenue | 0.16 | 0.28 | 0.73 | 0.44 | 0.11 |
| Stock-Based Compensation to Revenue | 0.09 | 0.06 | 0.23 | 0.18 | 0.13 |
| Income Quality | 1.31 | 0.48 | 1.01 | 0.79 | 0.49 |
Currency in CNY